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Introduction       
Background 
The issue of opioid use and misuse is
current and topical at present with reports
of opioid epidemics in the USA and the
increasing use of opioids in other parts of
the world. The New Scientist asserted
that America was in the throes of an
opioid epidemic1 with reports of fatalities
linked to physical contact with fentanyl.
Discussions have progressed from an
American focus to speculating on the
spread of this issue to UK cities, Glasgow
in particular.2,3 Safety issues have more
recently come to light (June 2018)
regarding the physical application and
management of specific drug forms e.g.
opioid transdermal patches (OTPs).4 The
prescribing, application and safe disposal
of opioid transdermal patches (OTPs)
within both healthcare settings and
personal dwellings is critical to the
effective use of these products.
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Background
The issue of opioid use and misuse is current and topical at
present with reports of opioid epidemics in the USA and the
increasing use of opioids in other parts of the world. The New
Scientist asserted that America was in the throes of an opioid
epidemic with reports of fatalities linked to physical contact
with fentanyl. Discussions have progressed from an American
focus to speculating on the spread of this issue to UK cities,
Glasgow in particular. Safety issues have more recently come
to light regarding the physical application and management of
specific drug forms e.g. opioid transdermal patches (OTPs).
The prescribing, application and safe disposal of OTPs within
both healthcare settings and personal dwellings is critical to
the effective use of these products. Healthcare professionals
have a duty of care and responsibility to ensure the safe
application and disposal of OTPs.
Aims
The aims of this study were to 1) gain insight into current
practices of healthcare professionals regarding OTPs (fentanyl
and buprenorphine) disposal practices and 2) identify 
Abstract
knowledge and system awareness surrounding the disposal
of these products in care home settings.  
Methods
We decided to focus on care homes due to the estimated
high prevalence of prescribing of OTPs in these care settings.
The study was undertaken by the University of Bradford
School of Pharmacy in 2015 and the participant sample
focussed on the North of England (UK).  
Results
The findings (based on 56 survey responses) displayed a
significant variation in current disposal practices and a lack
of specific working policies. We unearthed anomalies in the
participants’ knowledge of the active ingredient volume held in
depleted patches which, if not disposed of correctly, can lead
to harm. This has highlighted the need for more thorough
training and education on the safe and effective management
of OTPs.
Conclusions
Further education and training is needed regarding safe
disposal practices of OTPs, with the suggestion of
pharmacist-led interventions. This will minimise confusion and
reinforce safe disposal practices (denaturing products) and
support the reduction of unsafe disposal practices (domestic
waste or flushing). 
Keywords: opioid transdermal patches, care homes, disposal
practice, training.   
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Healthcare professionals have a duty of
care and responsibility to ensure the safe
application and disposal of OTPs.
There has been a steady increase in
the prescribing and use of transdermal
patches, especially in the elderly
population who maybe dependent on
caregivers to manage their medications in
particular for chronic conditions.5
Research by Rene et al found that 94.3%
of caregivers preferred the administration
of a transdermal patch over oral
rivastigmine for the treatment of
Alzheimer’s disease due to ease of
application of the patch over
administering oral medication and
reduced interference with the caregivers’
daily routine.6 Patient compliance and
acceptance were also increased when
using transdermal patches over other
routes of administration.7 Whilst the
transdermal delivery system has many
benefits, it has also been the source of
numerous patient safety incidents often
relating to their unsafe application and
disposal.8,9,10,11,12
The main focus in this study was to
investigate disposal practices of
transdermal opioid patches, which have
been subject to numerous Medicines
Healthcare products Regulatory Agency
(MHRA) medication safety alerts.
Particularly concerning have been reports
of accidental exposure to fentanyl
patches where cases have been reported
of patients swallowing patches or the risk
of them being transferred to other
individuals because they have not been
disposed of safely. The incorrect disposal
of patches by patients or healthcare
professionals has the potential for
patches to be diverted for misuse.
Reports are emerging where active
ingredients from OTPs have been
extracted and used by individuals with
substance misuse problems. This
highlights the importance of raising
awareness about the safe and effective
disposal practices in both the patient and
healthcare professional communities. 
In December 2015, NHS Wales issued
a patient safety notice to all healthcare
professionals highlighting reports of
ineffective application, removal and
disposal practices with fentanyl patches.
The alert made specific recommendations
advising healthcare professionals,
including those in nursing homes, to
ensure that patients and/or carers were
advised about safe disposal practices.13
The Care Quality Commission (CQC), in
2012, recommended that healthcare
professionals needed further training and
education around safe prescribing,
administration and, importantly, disposal
of fentanyl patches.14 The literature
demonstrates that the use of fentanyl
patches is high on the agenda of
medicines and health regulatory bodies
and has been for the past ten years with
the consistent theme of patient harm
emerging due to many factors, one being
inappropriate disposal of these products.
The introduction of Controlled Drug
Accountable Officers into healthcare
settings has reinforced the priority of
good and managed practice relating to
the use and safe disposal of these
products.15 Internationally, in 2012, the
US Food and Drug Administration (FDA)
reinforced the quality of information
provided to patients and caregivers
regarding disposal of fentanyl patches
after 26 case reports of paediatric
accidental exposure to fentanyl over the
past 15 years have resulted in 10 deaths
and 12 hospitalisations.16 
Incorrect disposal of OTPs has led to
paediatric fatalities due to accidental
exposure via ingestion and application of
patches. Alarms have been triggered
regarding these products based on
incidents such as OTPs being disposed in
a general waste bin within the home17
and poor disposal practices in a care
home which led to the death of a 2 year
old boy, Blake, who placed a discarded
fentanyl patch in his mouth during a visit
to his great grandmother.11 In June
2018 a further case of a 15 month old
child dying from accidental exposure to
fentanyl was reported widely in the
media.4 Although not directly a disposal
issue it does highlight the importance of
correct disposal practices, which can
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THE SAFE DISPOSAL OF FENTANYL PATCHES IN CARE HOMES IS
MOST IMPORTANT: Remove backing, fold over on itself and
place in a waste disposal or sharps bin - or use a CD denaturing kit.
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prevent further such cases. A recent study
by Breen et al regarding disposal practices
in UK care homes reported a need for the
implementation of training materials and
standardisation of guidelines across the
healthcare sector.18
Due to toxicity associated with OTPs
their effective disposal is essential for the
prevention of accidental exposure as used
patches still contain a high proportion of
active pharmaceutical ingredient. Research
has shown that there can be up to 80%
of residual drug remaining in a fentanyl
patch after three days continuous use.19
The current practice for the disposal of
OTPs as reported in multiple healthcare
settings is, once removed from the
patient, to fold the patch with the
adhesive side inwards, place the OTP
back inside the original sachet and
dispose of it via clinical waste or return it
to the supplying pharmacy. A reported
variation on this is that the folded patch
should then be placed back inside the
original sachet and disposed of via
domestic waste.
Within care homes the expected
practice is to remove the backing and fold
the patch over on itself. The patch would
then be placed into a waste disposal bin
or a CD denaturing kit20 or a yellow sharps
bin.21 This  is contrary to FDA guidance in
the home which recommends disposing
of used patches by folding them in half
with the sticky sides together, and then
flushing them down a toilet. They should
not be placed in the domestic waste
where children or pets can find them.22
Despite many safety alerts issued by
MHRA and FDA advising healthcare
professionals and patients on the safe
disposal of OTPs, there is a critical need to
safeguard patients/carers against
accidental pharmacological exposure
with these products through raising
awareness around correct disposal
practices, which will also limit the
inadvertent diversion of these products
for misuse purposes. The focus of this
study was to examine opioid transdermal
patch disposal in care homes and gain a
detailed understanding of systems,
knowledge and practices in relation to
disposal of OTPs. To our knowledge, we
are not aware of any study that has
specifically looked at OTP disposal
practices in the UK or internationally
despite numerous studies looking at
disposal of medicines broadly.23
Methods       
We approached participants for this
study and asked them to share their
views on OTP application, disposal and
education between September 2015 and
December 2015. The participants who
contributed to this study were healthcare
professionals working within a care
home setting who were involved with
medicines administration. Potential care
homes with or without nursing were
identified through the website
‘www.carehomes.co.uk’ in the
following areas: Bradford, Leeds,
Manchester. This yielded a very large
number of care home contacts; Bradford
79 leads, Leeds 172 leads and
Manchester 185 leads, which totalled
336 potential care homes that could be
included in this study. The authors (EM
and SI) then telephoned each care home
to ascertain willingness to participate and
this yielded an interest of 85 care homes.
Interested parties were then sent out
study information documentation and
consent forms based on personal
preferences (electronic or paper). Once
consent documents were received the
questionnaire was released to the
individuals based on personal preference
either electronically through Google forms
or a paper version posted out. Two weeks
after receiving the questionnaires care
homes were followed up by telephone by
EM and SI to check on progress with
completing the questionnaire.  
To ensure that all the information
gathered was of high quality a mixture of
qualitative and quantitative research
methods for the development of the
questionnaire were used, which enabled
a broader and deeper understanding of
the project and provided scope for a
more detailed analysis. A variety of both
closed-format and open-format question
types were used to encapsulate both
methodologies such as Guttman scaling,
Likert scaling, multi-choice and single
option questions. Thematic analysis was
undertaken to determine common areas
of focus as per the respondents’
responses. 
The questionnaire was piloted by
healthcare professionals (5 individuals)
including both nurses and pharmacists.
The feedback included improving the
clarity of answers and the appropriate
wording of questions. The pilot was used
to further develop the questionnaire
before being finalised and sent out to
care homes. 
Ethical approval was granted by the
University of Bradford ethics committee
(Ref: EC2172). 
Results       
The number of respondents who
participated in the study is shown in Table
1. The respondents were all healthcare
professionals with the responsibility of
administering OTPs within their role in
care homes. It is not possible to
“. . . there is a critical need to safeguard patients/carers against
accidental pharmacological exposure with these products through
raising awareness around correct disposal practices . . .”
accurately note the response rate for
the online surveys therefore only the
completed online numbers are
mentioned in Table 1.
OTP Disposal Practice 
The care home staff were asked a
number of questions pertaining to their
knowledge of current disposal practice
of OTPs (specifically fentanyl and
buprenorphine patches) and product
related characteristics that impacted on
safe and risk averse disposal. Following
patch removal from a patient’s skin,
participants were asked what their initial
course of action would be. Responses
provided indicated that: 
1) 63% of the staff fold the patch
inwards:
2) 30% immediately dispose of the
patch through clinical waste
3) 4% place the patch back into its
original packaging
4) 3% cut the patch in half or
immediately dispose of it through
general waste.
Folding was not reported in options 2
and 3 - but that is not to say that it did
not happen. 
Participants were asked how they
disposed of unwanted and used OTPs
within their care homes. Responses are
indicated in Figure 1. Responses listed as
‘Other’ were disposal via a DOOP Kit.
Participants were asked to select the
percentage range of residual drug
remaining in a patch once used for full
duration of treatment to check their
knowledge and understanding of OTP
product characteristics. The responses are
shown in Table 2.  
On the subject of ongoing training,
participants were asked if their care home
provided training relating to disposal of
medicines, and more explicitly relating to
OTPs, which informed the staff of correct
OTP disposal procedure. The majority
(66.7%) of participants said that within
their workplace they did not undergo
training in order to safely dispose of
patches as part of their continuous
professional development.
Participants were asked if they were
aware of the MHRA safety update issued
in 2014. The results showed that only
47.2% of the respondents were aware of
the update, with 52.8% unaware.
The questionnaire further explored
the views of participants to see if they
were aware of any policies or procedures
within the care home setting for OTP
disposal. 58.2% of participants stated
they were aware of specific policies, with
41.8% unaware of any policies in place.
When asked if there was a designated
lead person within the healthcare team
responsible for the disposal of unwanted
medicines, 53.7% of participants said
‘no’, while 46.3% of participants were
aware of a staff member tasked with
safely disposing of medicines. When
discussing final collection of OTP waste,
the practice reported again varied: 69%
of respondents stated that collections
took place on a monthly basis, 17% on a
weekly basis, 4% on a daily basis and
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Figure 1: OTP Disposal profile as determined by participant responses
Survey Format
Online
Paper
Total
Number of Responses
36
20
56
Table 1: Surveys completed
Amount of residual drug
in OTP once removed
for disposal
0-9%
10-30%
31-50%
51-80%
80-100%
Percentage of participants
who agreed to the
residual figure
65%
21%
8%
2%
4%
Table 2: Participants’ views on active drug levels in used OTPs
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10% said that these waste products were
not collected at all. 
Discussion       
Although this study is small scale it does
provide a brief snapshot of activity in UK
care homes relating to fentanyl and
buprenorphine patch disposal practices.
The results of this study yielded the
following insights, which are discussed
below in the five key themes shown. 
1) OTP disposal – practice and
process
The correct disposal of OTPs is vital in
preventing patient safety incidents from
occurring. Participants in this study were
asked to comment on how they dispose
of unwanted/used patches in their care
setting. A variety of responses were
recorded. The results showed that 39%
of respondents disposed of patches
through clinical waste and 28% disposed
of patches by returning them to the
pharmacy. The diverse responses in
disposal practice is not surprising
considering, as mentioned above, the
lack of guidance health care professionals
have in terms of disposing OTPs.  
Of particular concern within this study
was how divided respondents were
regarding their knowledge of the
quantity of residual active ingredients
once an OTP was removed for disposal.
This is an issue as previous research has
demonstrated that the amount of drug
remaining in a patch following three
days of continuous use can fall within
the range of 28.84% to 84.4% of the
original drug content.23 In this study,
86.6% of respondents believed there was
less than 30% of drug remaining in a
patch after use. There is a possibility that
healthcare professionals may perceive
OTPs as obsolete products after use and
not give due care and attention to
disposal because they do not perceive
that harm can occur. This aspect of the
OTP raises another ‘red flag’ concerning
not only the risk of harm of ineffective
OTP disposal to the patients/carers or
family but the magnitude of this risk (e.g.
the adverse impact to a patient or child or
patch ingestion or adhesion) and
increases the urgency within the NHS to
ensure that safe disposal procedures are
formulated and effective practice is
utilised in all care homes and healthcare
settings. 
2) OTP disposal – system
knowledge and awareness 
A number of points raised within this
study are a cause for concern. Healthcare
professionals who are not aware of the
considerable amount of drug remaining
in a patch once it has been used may
register these products as lower risk and
hence take less safety precautions. This,
coupled with the fact that used/discarded
OTPs are stored by the majority of
healthcare sites for a month prior to
collection (which appears to be the
industry norm), can carry additional risk.
The professionals’ responses were
split equally on the employment of a lead
staff member responsible for OTP
disposal. If this person was in post they
would ensure that the risk attached to
the product use, retention/storage,
disposal/collection was managed and
reduced (akin to the role of a Controlled
Drugs Accountable Officer). However,
care home providers at times are resource
deprived and therefore the more practical
solution may be to train and upskill all, or
at least the majority of staff,  in OTP safe
disposal as a standard element of their
job. 
At the time of collecting this data
(September to December 2015) only
7.5% of respondents were aware of
any adverse incidents regarding the
application and disposal of these
products (as an aside to the MHRA alert
in 2014). This again reinforces the need
for accurate and timely provision of
information that informs health
professionals, patients and carers of the
risks attached to OTPs and the correct
method of opioid patch disposal to avoid
personal risk and environmental
pollution. 
3) Communication 
The results of the study indicated that
52.8% of care staff were unaware of the
recent safety update issued in July 2014 by
the MHRA in regards to fentanyl patches,
which highlights a gap in communication
between healthcare professionals and
external governing bodies, a weakness in
in-company communication strategies or
both. Healthcare providers should have
systems in place and procedures where
medicine alerts which come through the
Central Alerting System can be accessed
by all healthcare professionals within the
organisation and appropriate action can
be taken within a timely manner. The
MHRA alerts are released to practicing
healthcare professionals, including
pharmacists. A strong emphasis is placed
on pharmacists to remind carers and
patients of the potential risk of accidental
patch transfer if patches are not disposed
of safely. As the majority of respondents
were unaware of this update, it indicates
room for improvement for this information
to cascade through the different
healthcare settings and may support a
case for the use of community or practice
pharmacists to go into healthcare settings
to reinforce this message. 
“Of particular concern . . . was how divided respondents were regarding
their knowledge of the quantity of residual active ingredients
once an OTP was removed for disposal.”
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The wider implication of this finding is
twofold: 1) the results have shown the
deficiency and inaccessibility of medicines
or patient safety alerts to healthcare
providers/professionals resulting in potential
patient harm and 2) the question of
accountability and responsibility to
ensure the alerts are acted up on and
whether support is required through a
pharmacist to ensure implementation.
From a regulatory perspective the Care
Quality Commission core standards of
inspection require healthcare providers
to have systems in place that ensure
patient safety notices, alerts and other
communications concerning patient
safety that require action are acted upon
within required timescales.     
4) Training 
Staff training regarding how to
effectively dispose of OTPs (fentanyl and
buprenorphine) was also raised as a
potential area of focus to reduce risk of
harm not only to patients but carers and
family members. The importance of safe
disposal of patches within care homes
and the wider impact on family was
highlighted through the tragic case of
Blake who died 2 days after visiting his
great grandmother.11 The design of good
procedures and protocols, and compliance
with these, would reduce any risk of
harm and therefore all used patches
could be accounted for and signed to say
they have been safely disposed. Tools to
support OTP application and disposal
(recording of the date, time and site of
application, removal and disposal of the
OTP by a healthcare professional) will
significantly reduce the risk around
unaccounted patches that have the
potential to cause harm. 
5) Pharmacists as experts in
medicines management guidance
and support 
The findings of this study indicate that
61% of care staff would refer to
pharmacists as their first port of call if
they required any further information on
application or disposal of patches. The
role of a pharmacist can be described as
an educator, particularly in care homes
where better utilisation of the
pharmacist’s skills and knowledge can
bring various benefits not only in
improving medicines management
processes but also medicines
optimisation. Pharmacists can raise
awareness of the impact of incorrect
disposal methods/routes e.g. risk of soil
and water contamination and/or risk of
third parties accessing used OTPs and
purposefully using them by extracting
their active ingredients for subsequent
injection or reusing patches. Furthermore,
the results from this study indicate that
care homes have no adequate guidance
or systems in place for staff to follow in
relation to OTP disposal. Pharmacists can
be used to develop robust systems around
the safe and effective disposal of OTPs. 
The value of a pharmacist’s
knowledge and skills is further supported
by the new plans set out by the NHS in
employing pharmacists in local GP surgeries
in patient-facing roles highlighting the
potential pharmacists have in providing
additional support as well as delivering
advice to patients. This has been
reinforced by the introduction of
pharmacists into care homes to support
medicines optimisation and advise on
better medicines systems for care homes
to reduce waste and inefficiency.24
Conclusions        
This study and subsequent analysis was
done in response to risks identified as a
result of poor OTP management within
the healthcare environment e.g.
accidental paediatric exposure and patch
transfer from elderly patients have been
reported by the MHRA (2008 and 2014)
and Greater Manchester Combined
Authority (2017). This study is by no
means comprehensive but aims to
highlight a significant risk attached to the
disposal of transdermal opioid patches.     
The results indicate the diversity in
current policies across different
healthcare settings as well as the
disjointed knowledge concerning the
practices currently being used when
disposing of patches. Only 9% of
respondents used the denaturing process
(DOOP Kit) to safely dispose of OTPs.
Other practices such as disposal via
flushing and domestic waste are totally
unacceptable and cause potential harm
to patients, the environment and society.
The returns to pharmacy and  disposal via
clinical and hazardous waste were all
favoured disposal methods but the
disparity of practice exhibited is of concern.
The study also indicated that there is
awareness of the level of residual active
ingredients in OTPs at the point of
disposal, and there is limited mandatory
guidance provided regarding product use
and disposal. From a system perspective
there does not appear to be consistent
training and practice regarding the safe
disposal of this product range and the
information channels whereby alerts and
vital information regarding these
products are passed to healthcare
professionals are underdeveloped. 
This study presents preliminary but
cautionary findings, and on this basis the
authors recommend that the following
elements be considered when effectively
managing OTP products (fentanyl and
buprenorphine):
• The main tool that can educate patient/
carers and healthcare professionals on
the correct and most effective method
of patch disposal is the Patient
Information Leaflet (PIL). Manufacturers
should ensure that the information
needed to dispose of such products is
clear and can be acted upon by carers
and staff and should make this a
separate document to the PIL.
• There is a need for a guidance
document which can be used in all
healthcare settings dictating the
mandatory practice to be followed
regarding OTP disposal. 
• As part of the medicines management
training all healthcare professionals
receive, particular focus should be
placed on the disposal of transdermal
opioid patches. This training could be
delivered by pharmacists who have
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expert knowledge about safe disposal
practices of medicines.  
• A tool should be developed which
fully audits the stages of application,
removal and most importantly
disposal of the patch. This will ensure
unaccounted patches are located and
thus disposed of safely. 
• We suggest that further research be
undertaken by Central Alerting
System to look at the best channel of
communication to ensure these alerts
reach all healthcare professionals, not
just managers, and, most importantly,
that they are acted upon. Several
alerts issued identified healthcare
professionals who were best
positioned to remind patient/carers of
safe disposal practices and this
information is not being cascaded
down. This study has identified this
from an OTP perspective but the
finding is generalisable to all alerts
concerning medicines and their
implementation.  
• More research needs to be
undertaken into the prevalence of
OTP safety incidents, incident
recording mechanisms, root cause
analysis and prevention mechanisms.
This data can be used to inform
guidance and process design. 
• Improved knowledge and
understanding, coupled with training
and education of OTP disposal,
should be considered to mitigate and
reduce the risk of harm from these
products. Pharmacists can play a key
role, working with other healthcare
professionals, to create essential
guidance and training materials
regarding the safe disposal of OTPs in
care home and other healthcare
settings.
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